Log in or Sign up for Free to view tailored content for your specialty!
Inflammatory Bowel Disease News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s
The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease, Lilly reported.
Long term autoimmune, autoinflammatory disease risk significantly higher after COVID-19
SARS-CoV-2 infection, especially a severe case or without vaccination, significantly increases the long-term risk for developing autoimmune and autoinflammatory connective tissue diseases, according to data published in JAMA Dermatology.
Log in or Sign up for Free to view tailored content for your specialty!
Biosimilar boom set to expand treatment landscape for IBD, inflammatory diseases in 2025
The expansion of safe and effective FDA-approved biosimilars for inflammatory bowel disease set to launch in early 2025 may improve access to care, with the potential to reduce health care costs and revolutionize the treatment landscape.
Celltrion's Steqeyma nabs FDA approval as seventh Stelara biosimilar
The FDA has approved the Stelara biosimilar Steqeyma for the treatment of adults and children with plaque psoriasis and psoriatic arthritis and adults with Crohn’s disease and ulcerative colitis, Celltrion announced in a press release.
How GIs can recapture GI with Larry Kosinski, MD
In this podcast episode, Larry Kosinski, MD, founder of SonarMD, discusses reclaiming GI services for patients and physicians, developing new tools for IBD patients and more.
AGA updates living guideline on pharmacological management of moderate to severe UC
In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.
Concomitant use of common medications does not significantly affect UC induction therapy
Baseline concomitant exposure to commonly used medications, such as corticosteroids and 5-aminosalicylates, did not significantly affect clinical and endoscopic outcomes during induction therapy in ulcerative colitis, data analysis showed.
FDA approves Yesintek, sixth Stelara biosimilar; launch slated for February
The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.
VIDEO: Subcutaneous guselkumab induction achieves clinical remission in Crohn’s disease
PHILADELPHIA — Subcutaneous guselkumab outperformed placebo and, as with IV administration, appears to have “profound induction effects” on both clinical remission and endoscopic response in Crohn’s disease, a presenter told Healio.
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read